Author:
Kucharz Jakub,Dumnicka Paulina,Giza Agnieszka,Demkow Urszula,Kusnierz–Cabala Beata,Demkow Tomasz,Wiechno Pawel
Publisher
Springer International Publishing
Reference37 articles.
1. Athar U, Gentile TC (2008) Treatment options for metastatic renal cell carcinoma: a review. Can J Urol 15(2):3954–3966
2. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A (2008) Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 68(6):394–424
3. Choueiri TK, Hessel C, Halabi S, Sanford B, Michaelson MD, Hahn O, Walsh M, Olencki T, Picus J, Small EJ, Dakhil S, Feldman DR, Mangeshkar M, Scheffold C, George D, Morris MJ (2018) Cabozantinib versus sunitinib as initial therapy for metastatic renal cell carcinoma of intermediate or poor risk (Alliance A031203 CABOSUN randomised trial): progression–free survival by independent review and overall survival update. Eur J Cancer 94:115–125
4. CTCAE (2010) version 4.03. U.S. Department of Health and Human Services NIH, National Cancer Institute. Common terminology criteria for adverse events. https://evs.nci.nih.gov/ftp1/CTCAE/CTCAE_4.03/CTCAE_4.03_2010–06–14_QuickReference_5x7.pdf . Accessed on 23 Feb 2019
5. Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S, Mooney M, Rubinstein L, Shankar L, Dodd L, Kaplan R, Lacombe D, Verweij J (2009) New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 45(2):228–247
Cited by
7 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献